Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Mol Cancer Res. 2019 May 1;17(8):1613–1626. doi: 10.1158/1541-7786.MCR-18-1235

Table 1.

Summary of clinicopathologic information of patients with TFE3-RCC.

Case # Sex Age Size(cm) Stage Fuhrman Grade Histological finding FISH fusion TFE3 GPNMB Cathepsin K RET
1 M 11 2.2 pT1a-Nx-Mx 3 Clear & papillary + ASPL-TFE3 2 2 - 1
2 F 16 9.0 pT2apN1M1 2 Clear & tubular + ASPL-TFE3 2 1 1 2
3 F 19 2.5 pT1a-Nx-Mx 2 Clear & papillary, calcification + SFPQ-TFE3 2 2 1 2
4 F 20 6.0 pT1b-Nx-Mx 3 Eosinophilic, alveolar, tubular + PRCC-TFE3 2 2 - 1
5 M 26 3.3 pT1a-Nx-Mx 2 Eosinophilic, alveolar, tubular + PRCC-TFE3 2 2 2 -
6 F 33 1.0 pT1a-Nx-Mx 2 Clear & alveolar + SFPQ-TFE3 2 1 1 -
7 M 52 2.7 pT1a-N2-M0 2 Clear & papillary + PRCC-TFE3 2 2 - 1
8 F 66 5.5 pT1b-Nx-Mx 1 Clear & multicystic, calcification + SFPQ-TFE3 1 2 2 2
9 F 73 2.5 pT3-Nx-Mx 3 Alveolar, papillary, Mixed clear and eosinophlic, psammoma body + ASPL-TFE3 2 2 1 2